Kymera Therapeutics, Inc. NASDAQ:KYMR

Founder-led company

Kymera Therapeutics stock price today

$42.57
+2.46
+6.13%
Financial Health
0
1
2
3
4
5
6
7
8
9

Kymera Therapeutics stock price monthly change

-5.18%
month

Kymera Therapeutics stock price quarterly change

-5.18%
quarter

Kymera Therapeutics stock price yearly change

+54.09%
year

Kymera Therapeutics key metrics

Market Cap
2.58B
Enterprise value
1.76B
P/E
-10.42
EV/Sales
37.67
EV/EBITDA
-11.63
Price/Sales
38.76
Price/Book
3.70
PEG ratio
0.27
EPS
-2.51
Revenue
79.41M
EBITDA
-160.19M
Income
-154.59M
Revenue Q/Q
8.67%
Revenue Y/Y
70.15%
Profit margin
-330.6%
Oper. margin
-344.37%
Gross margin
0%
EBIT margin
-344.37%
EBITDA margin
-201.72%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Kymera Therapeutics stock price history

Kymera Therapeutics stock forecast

Kymera Therapeutics financial statements

Average Price Target
Last Year

$58.6

Potential upside: 37.65%

Based on estimate of 5 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Kymera Therapeutics, Inc. (NASDAQ:KYMR): Profit margin
Jun 2023 16.51M -38.79M -234.96%
Sep 2023 4.72M -52.86M -1118.17%
Dec 2023 47.88M -14.36M -30.01%
Mar 2024 10.28M -48.55M -472.02%
Kymera Therapeutics, Inc. (NASDAQ:KYMR): Debt to assets
Jun 2023 581945000 146.51M 25.18%
Sep 2023 552378000 156.84M 28.39%
Dec 2023 575759000 180.78M 31.4%
Mar 2024 868251000 157.04M 18.09%
Kymera Therapeutics, Inc. (NASDAQ:KYMR): Cash Flow
Jun 2023 -35.25M 35.83M 1.30M
Sep 2023 -31.64M 60.51M -206K
Dec 2023 8.04M 18.95M 1.93M
Mar 2024 -39.59M -330.60M 353.75M

Kymera Therapeutics alternative data

Kymera Therapeutics, Inc. (NASDAQ:KYMR): Employee count
Aug 2023 174
Sep 2023 181
Oct 2023 181
Nov 2023 181
Dec 2023 192
Jan 2024 192
Feb 2024 192
Mar 2024 187
Apr 2024 187
May 2024 187
Jun 2024 186
Jul 2024 186

Kymera Therapeutics other data

95.17% -0.07%
of KYMR is owned by hedge funds
49.27M +81.43K
shares is hold by hedge funds

Kymera Therapeutics, Inc. (NASDAQ:KYMR): Insider trades (number of shares)
Period Buy Sel
Jan 2024 979014 13295
Feb 2024 0 51537
Mar 2024 0 841535
May 2024 0 2575
Jun 2024 0 35440
Jul 2024 0 493560
Aug 2024 2952448 5000
Sep 2024 0 13500
Dec 2024 0 2500
Transaction Date Insider Security Shares Price per share Total value Source
Option
ESPOSITO PAMELA director
Stock Option (Right to Buy) 2,500 $29.55 $73,875
Option
ESPOSITO PAMELA director
Common Stock 2,500 $29.55 $73,875
Sale
ESPOSITO PAMELA director
Common Stock 2,500 $49 $122,500
Option
ESPOSITO PAMELA director
Stock Option (Right to Buy) 8,500 $29.55 $251,175
Option
ESPOSITO PAMELA director
Common Stock 5,000 $14.18 $70,900
Option
ESPOSITO PAMELA director
Common Stock 8,500 $29.55 $251,175
Sale
ESPOSITO PAMELA director
Common Stock 6,350 $47.75 $303,187
Option
ESPOSITO PAMELA director
Stock Option (Right to Buy) 5,000 $14.18 $70,900
Sale
ESPOSITO PAMELA director
Common Stock 7,150 $48.75 $348,584
Option
ALBERS JEFFREY W. director Stock Option (Right to Buy) 5,000 $10.34 $51,700
Patent
Application
Filling date: 15 Jul 2020 Issue date: 8 Sep 2022
Application
Filling date: 15 Feb 2022 Issue date: 1 Sep 2022
Application
Filling date: 15 Feb 2022 Issue date: 1 Sep 2022
Grant
Filling date: 21 Sep 2018 Issue date: 14 Jun 2022
Grant
Filling date: 2 Dec 2019 Issue date: 7 Jun 2022
Grant
Filling date: 16 Oct 2020 Issue date: 3 May 2022
Grant
Filling date: 3 Jul 2019 Issue date: 5 Apr 2022
Application
Filling date: 29 Jul 2021 Issue date: 24 Feb 2022
Application
Filling date: 3 Jun 2021 Issue date: 23 Dec 2021
Application
Filling date: 2 Dec 2019 Issue date: 21 Oct 2021
Insider Compensation
Dr. Nello Mainolfi M.D., Ph.D. (1979) Co-Founder, Pres, Chief Executive Officer & Director $832,620
Dr. Jared A. Gollob (1964) Chief Medical Officer $577,210
Dr. Bruce L. Booth D.Phil., Ph.D. (1974) Co-Founder & Chairman
$26,530
Saturday, 7 December 2024
seekingalpha.com
Tuesday, 26 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Sunday, 3 November 2024
seekingalpha.com
Friday, 1 November 2024
zacks.com
Thursday, 31 October 2024
zacks.com
globenewswire.com
Thursday, 24 October 2024
zacks.com
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
globenewswire.com
Thursday, 10 October 2024
zacks.com
Wednesday, 9 October 2024
globenewswire.com
Sunday, 6 October 2024
seekingalpha.com
Wednesday, 25 September 2024
globenewswire.com
Friday, 6 September 2024
zacks.com
Wednesday, 28 August 2024
globenewswire.com
Wednesday, 21 August 2024
globenewswire.com
Tuesday, 20 August 2024
zacks.com
Monday, 19 August 2024
globenewswire.com
globenewswire.com
Saturday, 10 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
Wednesday, 7 August 2024
zacks.com
Wednesday, 31 July 2024
globenewswire.com
Tuesday, 16 July 2024
seekingalpha.com
Wednesday, 10 July 2024
zacks.com
Tuesday, 9 July 2024
fool.com
zacks.com
investopedia.com
  • What's the price of Kymera Therapeutics stock today?

    One share of Kymera Therapeutics stock can currently be purchased for approximately $42.57.

  • When is Kymera Therapeutics's next earnings date?

    Unfortunately, Kymera Therapeutics's (KYMR) next earnings date is currently unknown.

  • Does Kymera Therapeutics pay dividends?

    No, Kymera Therapeutics does not pay dividends.

  • How much money does Kymera Therapeutics make?

    Kymera Therapeutics has a market capitalization of 2.58B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 67.84% to 78.59M US dollars.

  • What is Kymera Therapeutics's stock symbol?

    Kymera Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KYMR".

  • What is Kymera Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Kymera Therapeutics?

    Shares of Kymera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Kymera Therapeutics's key executives?

    Kymera Therapeutics's management team includes the following people:

    • Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 46, pay: $832,620)
    • Dr. Jared A. Gollob Chief Medical Officer(age: 61, pay: $577,210)
    • Dr. Bruce L. Booth D.Phil., Ph.D. Co-Founder & Chairman(age: 51, pay: $26,530)
  • Is Kymera Therapeutics founder-led company?

    Yes, Kymera Therapeutics is a company led by its founders Dr. Nello Mainolfi M.D., Ph.D. and Dr. Bruce L. Booth D.Phil., Ph.D..

  • How many employees does Kymera Therapeutics have?

    As Jul 2024, Kymera Therapeutics employs 186 workers, which is 1% less then previous quarter.

  • When Kymera Therapeutics went public?

    Kymera Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 21 Aug 2020.

  • What is Kymera Therapeutics's official website?

    The official website for Kymera Therapeutics is kymeratx.com.

  • Where are Kymera Therapeutics's headquarters?

    Kymera Therapeutics is headquartered at 200 Arsenal Yards Boulevard, Watertown, MA.

  • How can i contact Kymera Therapeutics?

    Kymera Therapeutics's mailing address is 200 Arsenal Yards Boulevard, Watertown, MA and company can be reached via phone at 857 285 5300.

  • What is Kymera Therapeutics stock forecast & price target?

    Based on 5 Wall Street analysts` predicted price targets for Kymera Therapeutics in the last 12 months, the avarage price target is $58.6. The average price target represents a 37.65% change from the last price of $42.57.

Kymera Therapeutics company profile:

Kymera Therapeutics, Inc.

kymeratx.com
Exchange:

NASDAQ

Full time employees:

184

Industry:

Biotechnology

Sector:

Healthcare

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

200 Arsenal Yards Boulevard
Watertown, MA 02472

CIK: 0001815442
ISIN: US5015751044
CUSIP: 501575104